News Briefs ORI Capital wraps up sophomore life sciences fund at $260m ORI Fund II will invest in early-stage biotech companies. Lawrence Aragon|Iris Dorbian - 23 February 2024 Share A- A+ 100% Create an account to continue reading Gain instant access to our expert editorial analysis and in-depth insight. Register for free Already have an account? Sign in
